Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.
1. Above 18 years of age. 2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML). 3. Written informed consent. 4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.
Study Type
OBSERVATIONAL
Enrollment
10,000
PHQ-9 and GAD-7 questionnaire
Department of Hematology, Nanfang Hospital, Southern Medical University,
Guanzhou, China
RECRUITINGAssess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia
Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.